Patents by Inventor Frank Stephen Kalthoff

Frank Stephen Kalthoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES AND THE USE THEREOF AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
    Publication number: 20190382399
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Application
    Filed: December 18, 2018
    Publication date: December 19, 2019
    Inventors: Robin Alec Fairhurst, Pascal Furet, Frank Stephen Kalthoff, Andreas Lerchner, Heinrich Rueeger
  • Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors
    Patent number: 10202371
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: February 12, 2019
    Assignee: Novartis AG
    Inventors: Robin Alec Fairhurst, Pascal Furet, Frank Stephen Kalthoff, Andreas Lerchner, Heinrich Rueeger
  • OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES AND THE USE THEREOF AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS
    Publication number: 20160168145
    Abstract: The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.
    Type: Application
    Filed: February 18, 2016
    Publication date: June 16, 2016
    Applicant: NOVARTIS AG
    Inventors: Robin Alec Fairhurst, Pascal Furet, Frank Stephen Kalthoff, Andreas Lerchner, Heinrich Rueeger